期刊文献+

新疆维吾尔族患者CYP2C9和VKORC1基因多态性分布及不同种族间的比较 被引量:4

Distribution of the Genetic Polymorphism of CYP2C9 and VKORC1 in Uighurian Patients in Xinjiang and Comparison among Different Ethnic Populations
原文传递
导出
摘要 目的:为建立适合新疆维吾尔族患者的华法林个体化给药模型提供研究基础。方法:检测200例新疆维吾尔族患者中CYP2C9和VKORC1的基因型,并与世界不同种族人群基因型及等位基因频率进行比较。结果:新疆维吾尔族CYP2C9*1/*1基因型频率低于韩国、日本、美国及中国汉族,高于土耳其;*1/*2杂合突变型频率低于土耳其、瑞典、英国,高于韩国、日本及中国汉族;*1/*3杂合突变型频率高于日本、韩国、中国汉族、英国、美国;*3/*3基因频率高于上述人群(P<0.05)。新疆维吾尔族*1等位基因频率低于中国汉族、日本、韩国、美国,高于土耳其;*2等位基因高于中国汉族、日本、韩国,低于土耳其、瑞典、英国;*3等位基因高于中国汉族、日本、韩国、瑞典、英国和美国(P<0.05)。VKORC1-1639AA型频率高于美国、瑞典、英国,低于新加坡、日本、中国台湾、中国汉族;AG型频率高于新加坡、日本、中国台湾、中国汉族;GG型频率高于新加坡、日本、中国台湾、中国汉族,低于美国、瑞典、英国(P<0.05)。新疆维吾尔族A型等位基因频率低于中国汉族、中国台湾、日本、新加坡,高于美国、瑞典和英国;G型等位基因高于中国汉族、中国台湾、日本、新加坡,低于美国、瑞典、英国(P<0.05)。结论:新疆维吾尔族患者CYP2C9和VKORC1基因多态性分布与亚洲及欧美人群均存在明显差异。 OBJECTIVE:To provide basis for the establishment of warfarin individualized administration model that is suitable for Uighurian patients in Xinjiang. METHODS:The genotypes of CYP2C9 and VKORC1 in 200 Uighurian patients in xinjiang were detected and compared with the genotypes and allele frequency of different ethnic populations in world. RESULTS : The frequency of CYP2Cg*1/*1 homozygous wild type in Xinjiang Uighurian patients was lower than South Korea, Japan, the United States and Han nationality in China, higher than Turkey; the frequency of *1/*2 heterozygous mutant was lower than Turkey, Sweden and the United Kingdom, higher than South Korea, Japan and Han nationality in China; the frequency of *1/*3 heterozygous mutant was higher than Japan, South Korea, Han nationality in China, the United Kingdom and the United States; the frequency of *3/*3 was higher than the populations above(P〈0.05). *1 allele in Xinjiang Uighurian patients was lower than Han nationality in China, Japan, South Korea and the United States, higher than Turkey(P〈0.05). *2 allele was higher than Han nationality in China, Japan and South Korea, lower than Turkey, Sweden and the United Kingdom(P〈0.05). *3 allele was higher than Han nationality in China, Japan, South Korea, Sweden, the United Kingdom and the United States(P〈0.05). The frequency of VKORCl-1639AA in Xinjiang Uighurian patients was higher than the United States Sweden, the United Kingdom, lower than Singapore, Japan, Taiwan China and Han nationality in China. The frequency of type AG was higher than Singapore, Japan, Taiwan China, Han nationality in China. The frequency of type GG was higher than Singapore, Japan, Taiwan China, Han nationality in China, lower than the United States, Sweden and the United Kingdom(P〈0.05). Type A allele in Xinjiang Uighurian patients was lower than Han nationality in China, Taiwan China, Japan and Singapore, higher than the United States, Sweden and the United Kingdom; type G was higher th
出处 《中国药房》 CAS 北大核心 2015年第24期3332-3334,共3页 China Pharmacy
基金 新疆医科大学第一附属医院院内科研基金项目(No.2013ZRQN21)
关键词 维吾尔族 基因多态性 华法林 CYP2C9 VKORC1 Uygur nationality Gene polymorphism Warfarin CYP2Cg VKORC1
  • 相关文献

参考文献13

  • 1Wadelius M, Chen LY, Erikesson N, et al. Association of warfarin dose with genes involved in its action and metab- olism[J]. Hum Genet, 2007,121 ( 1 ) : 23. 被引量:1
  • 2Higashi MK, Veenstra DL, Kondo LM, et al. Associati- on between CYP2C9 genetic variants and anticoagula- tion-ra|ated outcomes during warfarin therapy[J]. JAMA, 2002,87(13): 1 690. 被引量:1
  • 3Sanderson S, Emery J, Higgins J. CYP2C9 gene varian- ts, drug dose, and bleeding risk in warfarin-treated pa- tients: a HuGEnet systematic review and meta-analysis[J]. Genet Med, 2005, 7 (2) : 97. 被引量:1
  • 4徐仁爱,戴大鹏,胡利明,杨莉萍,胡国新,蔡剑平.中国汉族人群CYP2C9常见多态性位点的检测及其与国外其他人群的比较研究[J].医学研究杂志,2011,40(6):27-30. 被引量:8
  • 5Imai J, Jeiri I, Mamiya K, et al. Polymorphism of the cy- tochrome P450 (CYP)2C9 gene in Japanese epileptic pa- tients: genetic analysis of the CYP2C9 locus[J]. Pharma- cogenetics, 2000,10( 1 ) : 85. 被引量:1
  • 6Yoon YR, Shon JH, Kim MK, et al. Frequency of cyto- chrome P450 CYP2C9 mutant alleles in a Korean popula- tion[J]. Brit d Clin Pharrnaco, 2001,51 ( 3 ) : 277. 被引量:1
  • 7Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequen- cy of cytochrome P450 CYP2C9 variants in a Turkish pop- ulation and functional relevance for phenytoin[J]. Brit J Clin Pharmaco, 1999,48 ( 3 ) : 409. 被引量:1
  • 8Wadelius M, Chen LY, Lindh JD, et al. The largest pro- spective warfarin-treated cohort supports genetic forecast- ing[J]. Blood, 2009,113 (4) : 784. 被引量:1
  • 9Taube J,Halsall D,Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment [J]. Blood,2000,96(5) : 1 816. 被引量:1
  • 10Dickmann LE, Rettie AE, Kneller MB, et al. Identifica- tion and functional characterization of a new CYP2C9 variant (CYP2C9"5) expressed among African Americans [J]. Mol Pharmaeol, 2001,60 ( 2 ) : 382. 被引量:1

二级参考文献57

共引文献22

同被引文献39

  • 1Villegas TB, Sanchez GF, Jaramillo VK, et al. Genotype frequen- cies of VKORC1 and CYP2C9 in native and Mestizo populations from Mexico, potential impact for coumarin dosing [ J ]. Gene, 2015,558 (2) :235 - 240. 被引量:1
  • 2Verhoef TI, Redekop WK, Daly AK, et al. Pharmaeogenetic- guided dosing of eoumarin nticoagulants : algorithms for warfarin, 1 and phenprocoumon [ J ]. Br J Clin Pharmacol, 2014,77(4) :626 -641. 被引量:1
  • 3D'Andrea G,D'Ambrosio RL, Di Pema P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variabili- ty in the dose-anticoagulant effect of warfarin [ J ]. Blood,2005,105 (2) :645 -649. 被引量:1
  • 4D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors [ J ]. Blood-Rev,2008,22 (3) : 127 - 40. 被引量:1
  • 5An SH, Lee E, Chang BC, et al. Association of gene polymor- phisms with the risk of warfarin bleeding complications at thera- peutic INR in patients with mechanical cardiac valves[ J ]. J Clin Pharm Ther,2014,39(5) :314 -318. 被引量:1
  • 6Luo SB, Li CB, Dai DP, et al. Characterization of a novel CYP2C9 mutation ( 1009C > A) detected in a warfarin-sensitive patient[ J]. J Pharmacol Sci ,2014,125 (2) : 150 - 156. 被引量:1
  • 7Aomori T,Fujita Y,Obayashi K, et al. Case report: dose adjust- ment of warfarin using genetic information and plasma concentra- tion monitoring[ J]. J Clin Pharm Ther,2014,39(3 ) :319 -321. 被引量:1
  • 8吕海芹,周文,杜长江,吕树蕰.华法林的临床应用[J].泰山医学院学报,2011,32(6):423-425. 被引量:3
  • 9王芳芳,郭心灵,李菲菲,郜莉娜,尤崇革.基于华法林药物基因组学的临床用药模型建立[J].分子诊断与治疗杂志,2012,4(2):89-94. 被引量:5
  • 10鲁晓春,李世英.中国人VKORC1基因多态性对华法林维持剂量影响的Meta分析[J].心肺血管病杂志,2012,31(3):259-263. 被引量:7

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部